Evidence map›Paper›PMID 36814302›Full record

ArticlePilot and feasibility studies2023

Protocol for a pilot randomised controlled trial to evaluate integrated support from pharmacist independent prescriber and third sector worker for people experiencing homelessness: the PHOENIx community pharmacy study.

Vibhu Paudyal, Richard Lowrie, Frances S Mair, Lee Middleton, Versha Cheed, Jennifer Hislop, Andrea Williamson, Nigel Barnes, Catherine Jolly, Karen Saunders and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 1 country.

Vibhu PaudyalSchool of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. v.paudyal@bham.ac.uk.ORCID http://orcid.org/0000-0002-4173-6490
Richard LowriePharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK. Richard.Lowrie@ggc.scot.nhs.uk.
Frances S MairGeneral Practice and Primary Care, Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Lee MiddletonBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Versha CheedBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Jennifer HislopHealthcare Improvement Scotland, Edinburgh, UK.
Andrea WilliamsonUndergraduate Medical School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Nigel BarnesNHS Birmingham and Solihull Mental Health Foundations Trust, Birmingham, UK.
Catherine JollyInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Karen SaundersOffice for Health Improvement and Disparities, Department of Health and Social Care, Birmingham, UK.
Natalie AllenSIFA Fireside, Birmingham, UK.
Parbir JagpalPharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK.
George ProvanSimon Community Scotland, Glasgow, UK.
Steven RossSimon Community Scotland, Glasgow, UK.
Carole HunterGlasgow City HSCP, Alcohol and Drug Recovery Services, Glasgow, UK.
Sarah TearneBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Andrew McPhersonPharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK.
Helena HeathNHS Birmingham and Solihull Mental Health Foundations Trust, Birmingham, UK.
Cian LombardPharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK.
Adnan ArafNHS Birmingham and Solihull Mental Health Foundations Trust, Birmingham, UK.
Emily DixonBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Amy HatchBirmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Jane MoirPharmacy Services, NHS Greater Glasgow and Clyde, Scotland, UK.
Shabana AkhtarNHS Birmingham and Solihull Mental Health Foundations Trust, Birmingham, UK.
Cancer Research UK Clinical Trials Unit · GBNHS Greater Glasgow and Clyde · GBBirmingham and Solihull Mental Health NHS Foundation Trust · GBUniversity of Birmingham · GBUniversity of Glasgow · GBGlasgow City Council · GBHealthcare Improvement Scotland · GB

Funding

Health Services and Delivery Research Programme NIHR133060
6 · The paper itself

Abstract

backgroundPeople experiencing homelessness (PEH) have complex health and social care needs and most die in their early 40 s. PEH frequently use community pharmacies; however, evaluation of the delivery of structured, integrated, holistic health and social care intervention has not been previously undertaken in community pharmacies for PEH. PHOENIx (Pharmacy Homeless Outreach Engagement Non-medical Independent prescribing Rx) has been delivered and tested in Glasgow, Scotland, by NHS pharmacist independent prescribers and third sector homelessness support workers offering health and social care intervention in low threshold homeless drop-in venues, emergency accommodation and emergency departments, to PEH. Building on this work, this study aims to test recruitment, retention, intervention adherence and fidelity of community pharmacy-based PHOENIx intervention.

methodsRandomised, multi-centre, open, parallel-group external pilot trial. A total of 100 PEH aged 18 years and over will be recruited from community pharmacies in Glasgow and Birmingham. PHOENIx intervention includes structured assessment in the community pharmacy of health, housing, benefits and activities, in addition to usual care, through weekly visits lasting up to six months. A primary outcome is whether to proceed to a definitive trial based on pre-specified progression criteria. Secondary outcomes include drug/alcohol treatment uptake and treatment retention; overdose rates; mortality and time to death; prison/criminal justice encounters; healthcare utilisation; housing tenure; patient-reported measures and intervention acceptability. Analysis will include descriptive statistics of recruitment and retention rates. Process evaluation will be conducted using Normalisation Process Theory. Health, social care and personal resource use data will be identified, measured and valued. DISCUSSION: If the findings of this pilot study suggest progression to a definitive trial, and if the definitive trial offers positive outcomes, it is intended that PHOENIx will be a publicly funded free-to-access service in community pharmacy for PEH. The study results will be shared with wider stakeholders and patients in addition to dissemination through medical journals and scientific conferences.

trial registrationInternational Clinical Trial Registration ISRCTN88146807. Approved protocol version 2.0 dated July 19, 2022.

Indexed as

Health inequalityHomelessnessIntegrated carePharmacist independent prescriber

Identifiers

PMID36814302
PMCPMC9946705
OpenAlexW4321480104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.